Nanoparticulation improves bioavailability of Erlotinib.

about

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

P2860

Q53134314-1FD08359-529F-4919-BEDB-C4C3930FC2D4

P2860

Nanoparticulation improves bioavailability of Erlotinib.

Item

http://www.wikidata.org/entity/Q38701944

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Nanoparticulation improves bioavailability of Erlotinib.

@en

type

Item

label

Nanoparticulation improves bioavailability of Erlotinib.

@en

prefLabel

Nanoparticulation improves bioavailability of Erlotinib.

@en

P1476

Nanoparticulation improves bioavailability of Erlotinib.

@en

P2093

Dae Kyong Kim

http://www.w3.org/2001/XMLSchema#string

In Chul Shin

http://www.w3.org/2001/XMLSchema#string

Joo Won Park

http://www.w3.org/2001/XMLSchema#string

Kab-Sig Kim

http://www.w3.org/2001/XMLSchema#string

Kunhong Kim

http://www.w3.org/2001/XMLSchema#string

Kyung Mi Yang

http://www.w3.org/2001/XMLSchema#string

Kyungmoon Park

http://www.w3.org/2001/XMLSchema#string

P2860

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

Cancer statistics, 2016

Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib

A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways.

Clinical pharmacokinetics of tyrosine kinase inhibitors.

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)

Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.

Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs

Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib.

P304

1557-1565

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03639045.2017.1326931

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28554216

http://www.w3.org/2001/XMLSchema#string

Nanoparticulation improves bioavailability of Erlotinib.

about

P2860

P2860

Nanoparticulation improves bioavailability of Erlotinib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698